Meeting
2024 ASCO Genitourinary Cancers Symposium
Population based trends in intravesical gemcitabine use among patients with high-risk non-muscle invasive bladder cancer.
Authors
Stephen B. Williams
University of Texas Medical Branch at Galveston, Galveston, TX
Stephen B. Williams , Jinghua He , Aeja Jackson , Andrea Ireland , Hiremagalur Parthasarathy Balaji , Wenxi Huang , Qian Shi , Lorie Ellis , Mukul Singhal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Other
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 699)
DOI
10.1200/JCO.2024.42.4_suppl.699
Abstract #
699
Poster Bd #
L21
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Study of real-world treatment patterns and adherence to bacillus Calmette-Guerin (BCG) in the context of guideline recommendations for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
First Author: Franklin D Gaylis
Poster
2023 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guérin for the treatment of high-risk, treatment-naïve, non-muscle invasive bladder cancer.
First Author: Ian M. McElree
Poster
2022 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
First Author: Ian Mitchell McElree
Poster
2020 Genitourinary Cancers Symposium
A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.
First Author: Gary D. Steinberg